Persistence of SARS CoV-2 S1 Protein in CD16+ Mono
Post# of 148110
(Total Views: 781)
Posted On: 06/26/2021 2:23:44 PM
Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) Up to 15 Months Post-Infection
"Non-classical monocytes were sorted from PASC patients using flow cytometric sorting and the SARS-CoV-2 S1 protein was confirmed by mass spectrometry. Cells from 4 out of 11 severe COVID-19 patients and 1 out of 26 also contained SARS-CoV-2 RNA. Non-classical monocytes are capable of causing inflammation throughout the body in response to fractalkine/CX3CL1 and RANTES/CCR5.
https://www.biorxiv.org/content/10.1101/2021.06.25.449905v1
*************************
Jun 25, 2021
Pfizer’s Tofacitinib Helps COVID-19 Patients with Pneumonia in Phase 2 Study in Partnership with Hospital Israelita Albert Einstein in Brazil
https://trialsitenews.com/pfizers-tofacitinib...in-brazil/
********************************
"Non-classical monocytes were sorted from PASC patients using flow cytometric sorting and the SARS-CoV-2 S1 protein was confirmed by mass spectrometry. Cells from 4 out of 11 severe COVID-19 patients and 1 out of 26 also contained SARS-CoV-2 RNA. Non-classical monocytes are capable of causing inflammation throughout the body in response to fractalkine/CX3CL1 and RANTES/CCR5.
https://www.biorxiv.org/content/10.1101/2021.06.25.449905v1
*************************
Jun 25, 2021
Pfizer’s Tofacitinib Helps COVID-19 Patients with Pneumonia in Phase 2 Study in Partnership with Hospital Israelita Albert Einstein in Brazil
https://trialsitenews.com/pfizers-tofacitinib...in-brazil/
********************************
(2)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼